Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 13 April 2018, 13:22 HKT/SGT
Share:
    

Source: Eisai
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
On the Development of a Potential New Treatment for Tuberculosis

TOKYO, Apr 13, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University, and the University of Chicago to develop a potential new treatment for tuberculosis (TB).

In this joint research program, compounds identified from Broad's Diversity-Oriented Synthesis chemical library will be modified to design molecules that demonstrate improved activity as TB treatments. Anti-TB activity will be researched through a new mechanism of action involving the inhibition of tryptophan synthase, an essential enzyme present in Mycobacterium sp.

TB is one of the top 10 causes of death worldwide, with 10.4 million new cases of TB infections resulting in 1.7 million deaths in 2016 alone. Existing anti-TB medicines were introduced several decades ago, but require long courses of treatments (six to nine months), resulting in poor compliance with treatment. In addition, resistance to existing TB treatments has emerged in various parts of the world. Therefore, there is an urgent need for novel anti-TB agents with shortened treatments period and new mechanisms of action.

The Global Health Innovative Technology Fund (GHIT Fund), an international non-profit organization headquartered in Japan, is funding this new joint research program. TB Alliance is serving as an advisor to the program.

Under its human health care (hhc) philosophy, Eisai is proactively forming partnerships with governments, international organizations, and other non-profit private sector organizations, aiming to expedite the development of new treatment methods for TB, malaria and neglected tropical diseases, and thereby contribute to these patients and their families.

About the Broad Institute

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community.

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to http://www.broadinstitute.org.

About Colorado State University (CSU)

Founded in 1870 as the Colorado Agricultural College, CSU is now among the nation's leading research universities. Located in Fort Collins, CSU currently enrolls more than 33,000 students, and has more than 1,800 faculty members working in eight colleges.

CSU is recognized as a premier research institution and routinely ranks as one of the top American universities without a medical school in research expenditures. In Fiscal Year 2017, CSU research expenditures totaled $338 million; this was the 10th consecutive year research expenditures at the university have topped $300 million. More information is available at www.colostate.edu(.

About The University of Chicago

The University of Chicago is a leading academic and research institution that has driven new ways of thinking since its founding in 1890. As an intellectual destination, the University draws scholars and students from around the world to its home in Hyde Park and campuses around the globe. The University provides a distinctive educational experience, empowering individuals to challenge conventional thinking and pursue research that produces new understanding and breakthroughs with global impact.

About the Global Health Innovative Technology Fund

The first of its kind in Japan, the GHIT Fund is a public-private partnership between the Japanese government, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome Trust, and UNDP. Launched in April 2013, the organization utilizes Japanese research and development (R&D) to fight neglected diseases. GHIT Fund invests and manages a portfolio of development partnerships aimed at neglected diseases that afflict the world's poorest people. GHIT Fund mobilizes Japanese pharmaceutical companies and academic and research organizations to engage in the effort to get new medicines, vaccines, and diagnostic tools to people who need them most. For more information, please visit: www.ghitfund.org.

About TB Alliance

TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB). Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia's Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Germany's Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Irish Aid, Indonesia Health Fund, National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Apr 13, 2018 13:22 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 20, 2018 17:50 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
Apr 19, 2018 11:07 HKT/SGT
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
Apr 2, 2018 12:44 HKT/SGT
Eisai Submits Supplemental New Drug Application to U.S. FDA
Mar 28, 2018 18:33 HKT/SGT
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
Mar 23, 2018 14:41 HKT/SGT
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Mar 23, 2018 13:40 HKT/SGT
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Feb 27, 2018 09:33 HKT/SGT
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: